




Radius Health, Inc.  
Investor Relations Department  
950 Winter St, North Building 1st Floor  
North Building 1st Floor  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: RDUS

Last Trade:	35.30
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	-0.34  (-0.954%)
Day Range	35.11 - 35.79
52-Week Range	31.58 - 55.97
Volume	539,248

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Oct 18, 2017*  
[Radius Health Receives FDA Fast Track Designation for Elacestrant \(RAD1901\)](#)
- Oct 13, 2017*  
[Radius Health to Present First Health Economics Data on TYMLOS™ \(abaloparatide\) Injection at the Academy of Managed Care Pharmacy Nexus 2017](#)
- Oct 9, 2017*  
[Radius Health to Announce Third Quarter 2017 Financial Results, Host Conference Call and Live Webcast on November 2, 2017](#)
- Sep 29, 2017*  
[Radius Health Initiates Phase 1 Clinical Trial of RAD140 for the Treatment of Hormone Receptor Positive Breast Cancer](#)
- Sep 22, 2017*  
[Radius Health to Present at Cantor Annual Global Healthcare Conference](#)

## Upcoming Events [\[ View all \]](#)

- Nov 2, 2017 4:30 PM ET*  
[Q3 Radius Health Inc Earnings Conference Call](#)
- Feb 24, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)